Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 13/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6631553 | 0.86 | ALDH1A1 (0.49) | FFAR1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL27427478 | 0.83 | CHRNB2 (0.48) | FFAR1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL4130181 | 0.83 | CPA3 (0.47) | FFAR1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL27587442 | 0.83 | CPA3 (0.47) | FFAR1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL3702042 | 0.81 | GABBR2 (0.47) | FFAR1CYP1A2CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL7364895 | 0.81 | F10 (0.54) | KMT2ASMN1; SMN2 | |
| SCHEMBL1670315 | 0.80 | FFAR1 (0.62) | FFAR1 | |
| Ethylene Glycol SCHEMBL27959589 | 0.80 | ABCB1 (0.43) | FFAR1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL10382406 | 0.79 | KMT2A (0.51) | FFAR1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL14945152 | 0.79 | CHRNB2 (0.53) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124737-A1 | ACRYLIC PLASTISOL VISCOSITY REDUCERS | EASTMAN CHEMICAL COMPANY (US) | 2009-05-14 | — | — | US | disclosed |
| US-20060135812-A1 | Thiol-based NAALADase inhibitors | TSUKAMOTO TAKASHI | 2006-06-22 | — | — | US | disclosed |
| US-6992215-B2 | Thiol-based NAALADase inhibitors | GUILDFORD PHARMACEUTICALS INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050154019-A1 | Substituted cyclic amine metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2005-07-14 | — | — | US | disclosed |
| US-20050137248-A1 | Substituted cyclic amine metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2005-06-23 | — | — | US | disclosed |
| US-20050101567-A1 | Substituted cyclic amine metalloprotease inhibitors | NATCHUS MICHAEL G (US) | 2005-05-12 | — | — | US | disclosed |
| US-20050085503-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC, | 2005-04-21 | — | — | US | disclosed |
| US-6872742-B2 | Substituted cyclic amine metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-29 | — | — | US | disclosed |
| US-6858628-B2 | Substituted cyclic amine metalloprotease inhibitors | THE PROCTOR & GAMBLE COMPANY (US) | 2005-02-22 | — | — | US | disclosed |
| US-6812364-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS; ANTICANCER AGENTS | GUILFORD PHARMACEUTICALS INC. | 2004-11-02 | — | — | US | disclosed |
| US-20040138260-A1 | Substituted cyclic amine metalloprotease inhibitors | PROCTER & GAMBLE COMPANY, THE | 2004-07-15 | — | — | US | disclosed |
| US-20030191163-A1 | Substituted cyclic amine metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-10-09 | — | — | US | disclosed |
| US-6586623-B2 | Carbocyclic mercaptans such as 3-carboxy-alpha-(3-mercapto-propyl) benzenepropanoic acid, used as N-acetylated alpha-linked acidic dipeptidase(NAALADase) inhibitors and for medical diadnosis | GUILFORD PHARMACEUTICALS INC. | 2003-07-01 | — | — | US | disclosed |
| US-20030105153-A1 | Substituted cyclic amine metalloprotease inhibitors | PROCTER & GAMBLE COMPANY, THE | 2003-06-05 | — | — | US | disclosed |
| US-6569855-B2 | Particularly zinc metalloprotease activity for treatment of variety of maladies involving inflammation and/or tissue integrity | THE PROCTER & GAMBLE COMPANY | 2003-05-27 | — | — | US | disclosed |
| EP-0927161-B1 | SUBSTITUTED CYCLIC AMINE METALLOPROTEASE INHIBITORS | PROCTER & GAMBLE (US) | 2002-10-16 | — | — | EP | disclosed |
| US-6417219-B1 | ENZYME INHIBITORS AND OSTEOARTHRITIS | THE PROCTOR & GAMBLE COMPANY | 2002-07-09 | — | — | US | disclosed |
| US-20020072517-A1 | Substituted cyclic amine metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2002-06-13 | — | — | US | disclosed |
| US-20020061877-A1 | Substituted cyclic amine metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135812-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, GGCT | FFAR1 4257/4885SLC1A3 222/4885SLC1A2 129/4885 |
| US-20020061877-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | FFAR1 2646/4885SLC1A3 1444/4885SLC1A2 1145/4885 |
| US-20050154019-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | FFAR1 3297/4885SLC1A3 1510/4885SLC1A2 1163/4885 |
| US-20030191163-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | FFAR1 2646/4885SLC1A3 1444/4885SLC1A2 1145/4885 |
| US-20040138260-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, MMP1, MMP25 | FFAR1 2833/4885SLC1A3 880/4885SLC1A2 823/4885 |
| US-20050137248-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | FFAR1 3297/4885SLC1A3 1510/4885SLC1A2 1163/4885 |
| US-20050101567-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | FFAR1 3297/4885SLC1A3 1510/4885SLC1A2 1163/4885 |
| US-20020072517-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | FFAR1 2646/4885SLC1A3 1444/4885SLC1A2 1145/4885 |
| US-20030105153-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | FFAR1 2646/4885SLC1A3 1444/4885SLC1A2 1145/4885 |
| US-20050085503-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, FOLH1 | FFAR1 4171/4885SLC1A3 206/4885SLC1A2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.